TY - JOUR
T1 - Understanding FLT3 Inhibitor Resistance to Rationalize Combinatorial AML Therapies
AU - Shastri, Aditi
AU - Gonzalez-Lugo, Jesus
AU - Verma, Amit
N1 - Funding Information:
A. Shastri reports research funding from Kymera Therapeutics, consulting fees from GLG and Guidepoint, and honoraria from OncLive. A. Verma reports research funding from Bristol-Myers Squibb, Janssen, MedPacto, Novartis, Curis, Prelude, and Eli Lilly and Company; compensation as a scientific advisor to Novartis, Stelexis Therapeutics, Acceleron Pharma, and Celgene; and equity ownership in Throws Exception and Stelexis Therapeutics. No disclosures were reported by the other authors.
Publisher Copyright:
©2020 American Association for Cancer Research.
PY - 2021/3/1
Y1 - 2021/3/1
N2 - Summary: Patients treated with Fms-like tyrosine kinase 3 (FLT3) inhibitor–based acute myeloid leukemia therapies nearly always develop resistance. In this issue, Alotaibi and colleagues describe the patterns of mutations that emerge upon relapse after FLT3 inhibitor therapy after initial response, as well as in treatment-refractory disease in a single-institution study; the findings offer insights for sequential therapies targeting the dominant clone at the time of relapse.
AB - Summary: Patients treated with Fms-like tyrosine kinase 3 (FLT3) inhibitor–based acute myeloid leukemia therapies nearly always develop resistance. In this issue, Alotaibi and colleagues describe the patterns of mutations that emerge upon relapse after FLT3 inhibitor therapy after initial response, as well as in treatment-refractory disease in a single-institution study; the findings offer insights for sequential therapies targeting the dominant clone at the time of relapse.
UR - http://www.scopus.com/inward/record.url?scp=85137762526&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85137762526&partnerID=8YFLogxK
U2 - 10.1158/2643-3230.BCD-20-0210
DO - 10.1158/2643-3230.BCD-20-0210
M3 - Review article
C2 - 34661152
AN - SCOPUS:85137762526
SN - 2643-3249
VL - 2
SP - 113
EP - 115
JO - Blood cancer discovery
JF - Blood cancer discovery
IS - 2
ER -